Viewing Study NCT07465718


Ignite Creation Date: 2026-03-26 @ 3:20 PM
Ignite Modification Date: 2026-03-31 @ 9:05 PM
Study NCT ID: NCT07465718
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-12
First Post: 2026-03-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
Sponsor: Orphalan
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module